DEA Plays Whack-A-Mole With Unpronounceable Designer Drug
Published Date: 12/11/2025
Rule
Summary
The DEA is extending the temporary ban on MDMB-4en-PINACA, a powerful synthetic drug, keeping it in the strictest control category (Schedule I) for another year until December 12, 2026, or until a permanent decision is made. This means anyone making, selling, or using this drug faces serious legal consequences. The extension helps keep communities safe while the government finishes its review.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Schedule I Status Extended One Year
The DEA extended the temporary Schedule I listing for MDMB-4en-PINACA effective December 12, 2025 through December 12, 2026, or until a permanent decision is made. That means anyone who makes, sells, imports, exports, or possesses this drug continues to face the regulatory controls and civil and criminal penalties that apply to Schedule I substances.
Research and Teaching Still Restricted
Researchers, educators, and laboratories that engage in research, instructional activities, or chemical analysis involving MDMB-4en-PINACA remain subject to Schedule I controls and to the same administrative, civil, and criminal sanctions. Those activities remain restricted under this temporary order for the one-year extension.
Salts and Isomers Also Controlled
The temporary extension explicitly covers MDMB-4en-PINACA as well as its salts, isomers, and salts of isomers whenever such variants exist. That means chemical variants of MDMB-4en-PINACA are treated the same as the named compound under Schedule I during the extension period.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-22518, Safety Zone; Patapsco River, Baltimore, MD
On December 13, 2025, from 9:30 to 10:30 p.m., the Coast Guard is setting up a temporary safety zone around a barge in Baltimore’s Patapsco River for a fireworks show. Boats and people can’t enter this 300-foot zone unless the Coast Guard says it’s okay. This keeps everyone safe from fireworks hazards without causing any fees or long delays.
Next: 2025-22545, Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Fisheries of the Northeastern United States; 2025-2027 Atlantic Herring Fishery Specifications
Starting December 11, 2025, Atlantic herring fishers in the Northeast get a big boost with catch limits rising up to 237% for 2026 and 2027! These changes help protect herring populations while letting fishermen catch more, based on fresh science. This means a healthier ocean and better fishing opportunities for the next three years.